NCT00610129

Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)

A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test a new drug for neuroendocrine tumors. We think that this new drug may help control your tumor. MK-0646 is a monoclonal antibody. An antibody is a protein that is able to attach to specific target on cancer cells. This target helps the cancer cells grow and divide. By attaching to the target, it may stop the cancer cells from further growth and dividing. This study will help find out if MK-0646 is a helpful drug when taken in patients with neuroendocrine tumor. This study is a phase 2 study. The purpose of a phase 2 study is to find out what effects, good and/or bad, MK-0646 has on metastatic neuroendocrine tumors.

Conditions

• Neuroendocrine Tumors
• Metastatic Neuroendocrine Tumors

Interventions

Type	Name	Description
DRUG	MK-0646	MK-0646 (20 mg/mL) in sterilized solution for IV infusion (12.7 mL to deliver 12.0 mL) will be used for a dose of 10 mg/kg IV weekly administered over 60 minutes.

Timeline

• Start date: 2008-01-01
• Primary completion: 2010-01-01
• Completion: 2010-01-01
• First posted: 2008-02-07
• Last updated: 2015-11-20
• Results posted: 2015-11-20

Locations

5 sites across 1 country: United States